We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-9.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$155M
AUM Growth
-$12.2M
(-7.3%)
Cap. Flow
+$10.8M
Cap. Flow
% of AUM
6.97%
Top 10 Holdings %
Top 10 Hldgs %
72.2%
Holding
43
New
7
Increased
12
Reduced
13
Closed
11
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
2.1
quarters
Top 20 Avg Time Held Equity + Options
3.2
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
2.3
quarters
Top 20 Avg Time Held Equity only
3.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MeiraGTx Holdings
MGTX
|
+$5.86M |
| 2 |
Charles River Laboratories
CRL
|
+$4.94M |
| 3 |
Cue Biopharma
CUE
|
+$4.82M |
| 4 |
Prothena Corp
PRTA
|
+$4.53M |
| 5 |
Shattuck Labs
STTK
|
+$3.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$5.9M |
| 2 |
Encompass Health
EHC
|
+$5.4M |
| 3 |
Oscar Health
OSCR
|
+$5.12M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.18M |
| 5 |
Morphic Holding, Inc. Common Stock
MORF
|
+$3.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.33% |
| 2 | Miscellaneous | 8.26% |
| 3 | Industrials | 1.41% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
NeoGenomics
NEO
$2.14B
| $772K | 0.5% |
+63,524
| New | +$1.34M |
2022 Q1
0 quarters
|
|
27
PUT
Organon & Co
OGN
$3.62B
| $699K | 0.45% |
+20,000
| New | +$684K |
2022 Q1
0 quarters
|
|
28
Cognition Therapeutics
CGTX
$76.2M
| $660K | 0.43% |
240,080
-61,899
| -20% | -$239K |
2021 Q4
1 quarter
|
|
29
ProQR Therapeutics
PRQR
$209M
| $542K | 0.35% |
599,288
+242,671
| +68% | +$813K |
2020 Q4
5 quarters
|
|
|
SIOX
30
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $449K | 0.29% |
670,300
-131,880
| -16% | -$112K |
2021 Q1
4 quarters
|
|
31
Iovance Biotherapeutics
IOVA
$6.57B
| $333K | 0.22% |
20,000
-48,800
| -71% | -$755K |
2021 Q2
3 quarters
|
|
32
DELISTED
Cymabay Therapeutics
CBAY
| $292K | 0.19% |
93,923
-72,852
| -44% | -$229K |
2021 Q4
1 quarter
|
|
33
Moderna
MRNA
$86.3B
| – | – |
-3,700
| Closed | -$940K | – |
|
34
PUT
Progyny
PGNY
$2.1B
| – | – |
-50,000
| Closed | -$2.52M | – |
|
35
Procept Biorobotics
PRCT
$1.09B
| – | – |
-20,000
| Closed | -$500K | – |
|
|
36
CALL
Prothena Corp
PRTA
$429M
| – | – |
-52,100
| Closed | -$2.57M | – |
|
37
PUT
West Pharmaceutical
WST
$26.2B
| – | – |
-1,500
| Closed | -$704K | – |
|
38
Exicure
XCUR
$7.53M
| – | – |
-16,177
| Closed | -$490K | – |
|
|
39
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – |
-72,898
| Closed | -$3.45M | – |
|
|
PANA
40
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
| – | – |
-195,855
| Closed | -$1.9M | – |
|
|
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-45,000
| Closed | -$4.18M | – |
|
|
ODT
42
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| – | – |
-298,900
| Closed | -$404K | – |
|
|
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-362,909
| Closed | -$5.9M | – |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q1 2022 Portfolio in Review
As of Q1 2022, Prosight Management held 43 positions worth $155M, down 7.3% from $167M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Prosight Management deployed $10.8M of net new capital in Q1 2022, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was MeiraGTx Holdings: 380,700 shares worth $5.27M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Encompass Health, an estimated $5.4M trimmed.
- Prosight Management's largest Q1 2022 buy was MeiraGTx Holdings: 380,700 shares worth $5.27M.
- Prosight Management added most to Charles River Laboratories in Q1 2022, an estimated $4.94M increase.
- Prosight Management's biggest Q1 2022 reduction was Encompass Health, cutting an estimated $5.4M.
- Prosight Management fully exited Zogenix, Inc. in Q1 2022, selling an estimated $5.9M.
- Prosight Management's ten largest holdings make up 72% of its $155M portfolio in Q1 2022.
- Prosight Management opened 7 new positions and closed 11 in Q1 2022.
- Prosight Management's portfolio value fell 7.3% quarter-over-quarter to $155M.
Based on Prosight Management's 13F filing for Q1 2022, filed 16 May 2022.